Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL...
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
- Associated Therapies
- -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 56
- Registration Number
- NCT06413056
- Locations
- 🇪🇬
Ain Shams University Hospitals, Cairo, Abbassia, Egypt
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Brasilia
- Target Recruit Count
- 100
- Registration Number
- NCT06040489
- Locations
- 🇧🇷
Hospital Universitario de Brasilia, Brasilia, DF, Brazil
Bioequivalence of Amphotericin B Liposome for Injection
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 32
- Registration Number
- NCT05913921
- Locations
- 🇨🇳
Haikou people's Hospital, Haikou, Hainan, China
Pharmacokinetics and Safety of AmBisome and DKF-5122
- Conditions
- Interventions
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Dongkook Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05749380
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05541107
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-11-27
- Target Recruit Count
- 30
- Registration Number
- NCT05468372
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
AmB Dose for Cryptococcal Meningitis
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04140461
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT04031833
- Locations
- 🇺🇬
Infectious Disease Institute, Kampala, Uganda
Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Cornea Research Foundation of America
- Registration Number
- NCT04018417
- Locations
- 🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
Short Course Regimens for Treatment of PKDL (Sudan)
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 110
- Registration Number
- NCT03399955
- Locations
- 🇸🇩
Prof. Elhassan Centre for tropical Medicine, Doka, Gedaref, Sudan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.